Anti-radiation drugs are medications used to treat or reduce the harmful effects of ionizing radiation on the body such as those caused by radioactive material or radiation therapy. These drugs work by protecting healthy cells and tissues from damage caused by radiation exposure. Some key anti-radiation drugs include Amifostine, TraumaCure, EPO, and PR39. Amifostine is administered as a cytoprotective agent to reduce the effects of chemotherapy and radiation therapy. TraumaCure promotes accelerated wound healing and reduces inflammation for patients undergoing radiation therapy.
The global anti radiation drugs market is estimated to be valued at US$ 587.4 Mn in 2023 and is expected to exhibit a CAGR of 9.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Increasing risks from radiation exposure is a key driver fueling growth of the anti radiation drugs market. Factors such as rising use of radiation therapy techniques in cancer treatment, nuclear weapons development, nuclear plant accidents, and space exploration are contributing to higher risks of radiation exposure. According to the World Health Organization (WHO), every year around 40,000 new cases of thyroid cancer are diagnosed which is caused due to exposure to ionizing radiation. Anti-radiation drugs help minimize the harmful impact of radiation exposure on human health. Amifostine, for instance, is FDA approved for reduction of damage from kidney treatment with x-ray therapy. The increasing installation of nuclear power plants worldwide is also propelling demand for anti-radiation drugs to protect plant workers from occupational radiation hazards. For example, the global nuclear power fleet has increased by around 25% since 2010 with around 450 nuclear power reactors currently operating across 31 countries.
SWOT Analysis
Strength: Anti Radiation Drugs provide protection against damaging radiation during radiation therapy for cancer treatment, diagnostic tests involving radiation exposure, and accidental exposure to radiation. Some anti radiation drugs, such as amifostine, are preferentially taken up by non-cancerous cells, reducing harm to healthy tissues. Amifostine can reduce xerostomia (dry mouth) in patients receiving radiation therapy for head and neck cancers.
Weakness: Many anti radiation drugs have side effects like nausea, vomiting, low blood pressure, and allergic reactions which may decrease patient compliance. Their effectiveness depends on radiation quality, dosage, and exposure time.
Opportunity: Growing cancer burden worldwide and increasing use of radiation therapy and nuclear medicine procedures offer several opportunities for anti radiation drug manufacturers. Development of safe and selective radiation protectors with minimal side effects can widen the market potential.
Threats: Stringent regulatory hurdles and long approval times for new anti radiation drugs pose major threats. Substitution threat also exists from adoption of alternative cancer treatments involving immunotherapy, gene therapy or optimized radiation protocols.
Key Takeaways
The global anti radiation drugs market size is expected to witness high growth driven by rising cancer incidence, growing acceptance of radiation therapy, increasing diagnostic and therapeutic applications of nuclear medicine. The global anti radiation drugs market is estimated to be valued at US$ 587.4 Mn in 2023 and is expected to exhibit a CAGR of 9.6% over the forecast period 2023 to 2030.
Regional analysis indicates North America currently dominates the market owing to regulatory approvals, reimbursement policies, growing elderly population and high healthcare spending in the region. Europe and Asia Pacific are fastest growing regional markets with increasing cancer burden, healthcare infrastructure development and government initiatives supporting market growth.
Key players operating in the anti radiation drugs market are DIC Corporation, Dow Chemical Company, BASF SE, Arkema Group, Celanese Corporation, Trinseo, The Lubrizol Corporation, Wacker Chemie AG, Synthomer Plc, and Asahi Kasei Corporation. These companies are actively engaged in new product development and expansion through partnerships to strengthen their market position. Increasing demand and potential of emerging markets is attracting several small and medium players in the anti radiation drugs space.
Get more insights on this topic: https://www.trendingwebwire.com/anti-radiation-drugs-market-size-and-outlook-2023-2030/
